Literature DB >> 7989744

Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes.

A G Brooks1, P L Campbell, P Reynolds, A M Gautam, J McCluskey.   

Abstract

The behavior of mouse I-Ak molecules was studied in the human Ag presentation mutants T2 and 9.5.3, which contain deleted or mutated HLA DM genes. HLA class II molecules expressed by these APC are defective in presentation of native Ag and are mostly complexed with class II-associated invariant chain peptides (CLIP). In contrast to human class II molecules, a significant proportion of mouse I-Ak molecules expressed in T2 and 9.5.3 were associated with antigenic peptides, indicating that I-Ak/peptide assembly is possible in the absence of the Dm proteins. Thus, the presentation of determinants derived from hen egg lysozyme (HEL), keyhole limpet hemocyanin, and conalbumin was normal in 9.5.3Ak and a conalbumin determinant was presented normally by T2.Ak. However, the keyhole limpet hemocyanin determinant was not presented by T2.Ak, and HEL46-61 was only presented at a low level by these APC. SDS-stable, dimeric I-Ak molecules were expressed by both T2.Ak and 9.5.3Ak and formed late in their intracellular transport. Presentation of HEL46-61 was partially inhibited by disrupting vacuolar acidification in 9.5.3Ak, consistent with I-Ak/peptide assembly in a post-Golgi endosomal compartment. Accordingly, Dm is not an obligatory requirement for MHC class II/peptide assembly. We propose that Dm influences the displacement of CLIP from recently synthesized class II molecules, a process that is likely to be less critical for I-Ak because of its low affinity for CLIP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989744

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Distinct recognition by two subsets of T cells of an MHC class II-peptide complex.

Authors:  Zheng Pu; Javier A Carrero; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

Review 2.  Protein sorting within the MHC class II antigen-processing pathway.

Authors:  M S Marks
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 3.  Selection of the MHC class II-associated peptide repertoire by HLA-DM.

Authors:  S O Arndt; A B Vogt; G J Hämmerling; H Kropshofer
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

4.  Distinct antigen MHC class II complexes generated by separate processing pathways.

Authors:  R Lindner; E R Unanue
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

Review 5.  HLA-DM: arbiter conformationis.

Authors:  Andrea Ferrante
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

6.  Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.

Authors:  T D Armstrong; V K Clements; B K Martin; J P Ting; S Ostrand-Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

7.  Deficient antigen-presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome.

Authors:  S Kovats; G T Nepom; M Coleman; B Nepom; W W Kwok; J S Blum
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.

Authors:  H Kropshofer; A B Vogt; G J Hämmerling
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

Review 9.  Generation of MHC class II-peptide ligands for CD4 T-cell allorecognition of MHC class II molecules.

Authors:  Scott A Leddon; Andrea J Sant
Journal:  Curr Opin Organ Transplant       Date:  2010-08       Impact factor: 2.640

10.  Antigen processing and presentation by a murine myoblast cell line.

Authors:  M J Garlepp; W Chen; H Tabarias; M Baines; A Brooks; J McCluskey
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.